Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.30 |
| ▸ | QPCT | Q16769 | 2/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL843993 | 0.88 | MAP2K1 (0.37) | MAP2K1PDE3BPDE3AP2RY12ESR1 | |
| SCHEMBL859794 | 0.88 | MAP2K1 (0.37) | MAP2K1PDE3BPDE3AP2RY12ESR1 | |
| SCHEMBL844826 | 0.88 | MAP2K1 (0.37) | MAP2K1PDE3BPDE3AP2RY12ESR1 | |
| SCHEMBL10076793 | 0.88 | MAP2K1 (0.37) | MAP2K1PDE3BPDE3AP2RY12ESR1 | |
| SCHEMBL843963 | 0.87 | MAP2K1 (0.41) | MAP2K1PDE3BPDE3AP2RY12ESR1 | |
| SCHEMBL13950768 | 0.87 | MAP2K1 (0.41) | MAP2K1PDE3BPDE3AP2RY12ESR1 | |
| SCHEMBL843962 | 0.87 | MAP2K1 (0.41) | MAP2K1PDE3BPDE3AP2RY12ESR1 | |
| SCHEMBL858440 | 0.86 | MAP2K1 (0.39) | MAP2K1PDE3BPDE3AP2RY12ESR1 | |
| SCHEMBL844360 | 0.86 | MAP2K1 (0.41) | MAP2K1PDE3BPDE3AP2RY12ESR1 | |
| SCHEMBL13950575 | 0.86 | MAP2K1 (0.39) | MAP2K1PDE3BPDE3AP2RY12ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557221-B2 | Substituted hydantoins | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090048452-A1 | (R)-5-[4-(2-Hydroxy-ethoxy)-phenyl]-3-[(S)-1-(6-iodo-1H-benzoimidazol-2-yl)-2-phenyl-ethyl]-imidazolidine-2,4-dione; map kinase inhibitors; antihyperproliferative agents | CHEN SHAOQING | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048452-A1 | (R)-5-[4-(2-Hydroxy-ethoxy)-phenyl]-3-[(S)-1-(6-iodo-1H-benzoimidazol-2-yl)-2-phenyl-ethyl]-imidazolidine-2,4-dione; map kinase inhibitors; antihyperproliferative agents | MAPK1, MAP3K2, MAP3K1 | MAP2K1 35/4885PDE3B 3032/4885PDE3A 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.